			ICMJE DISCLOSURE FO	RM	
Date:			3/1/2024		
Your Name: Manuscript Title:			Dr. Arun Madhab Boruah Effect of norethisterone dose and duration in the management of abnormal uterine bleeding: A review		
M	anuscript Number (if I	known):	Click or tap here to enter text.		
oc aff in The ep th	ntent of your manuscr fected by the content of dicate a bias. If you are se author's relationship didemiology of hyperte at medication is not m	ript. "Rela of the ma e in doubt os/activition entioned all suppo	ated" means any relation with for-profit or no nuscript. Disclosure represents a commitmer t about whether to list a relationship/activity/ es/interests should be defined broadly. For e u should declare all relationships with manufa in the manuscript.	finterest, it is preferable that you do so.	
+			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	STATE OF THE REAL PROPERTY.		Time frame: Since the initial planning	g of the work	
1	All support for the present	⊠ N	lone		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.				
				Oge set to lay it add ablood man.	
			Time frame: past 36 mont	hs	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ N	one		
3	Royalties or licenses	⊠ N	one		
4	Consulting fees	⊠ ,	None		
112	/13/2021ICMUE Disclosure F	olom)	Dr. Arun Madfieb Borush MD, Ph.D. FICOG, FICMCH, FICRM Read, No. 19432 (AMC)		

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational	
honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational	
lectures, presentations, speakers bureaus, manuscript writing or educational	
events	
6 Payment for expert testimony None	
7 Support for attending meetings and/or travel	
8 Patents Splanned.	
issued or pending	
9 Participation on a Data Safety Monitoring Board or Advisory Board	
Leadership or fiduciary role in other board, society, committee or advocacy	
group, paid or unpaid 11 Stock or stock options None	
Opinion 8	

equi mat drug writi	eipt of ipment, erials, gs, medical ing, gifts or er services	None Gynaset – CR 10 from Mankind Pharma Ltd	
	Other financial or non-financial interests	⊠ None	
inte			

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Dr. Arun Madhab Boruah MD, Ph.D, FICOG, FICMCH, FICRM Read No.: 9432 (AMC)

equipment, materials, days, medical	Gynaset – CR 10 from Mankind Pharma Ltd
writing, gifts or other services	
Other financial or non-financial interests	™ None
microsta	
	drugs, medical writing, gifts or other services

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

O/ O'S 844 Dr. Arun Madhab Boruah MD, Ph.D, FICOG, FICMCH, FICRM Read No.: 9432 (AMC)

Effect of norethisterone dose and duration in the management of abnormal uterine

2/20/2024

Dr. DIBYENDU BANERJEE

Date:

3

Your Name:

Manuscript Title:

Manuscript Number (if known): NILL

affected by the a bias. If you a The author's re epidemiology of that medication	of transparency, we ask you to disclose all relationships/active manuscript. "Related" means any relation with for-profit or content of the manuscript. Disclosure represents a committee in doubt about whether to list a relationship/activity/interactionships/activities/interests should be defined broadly. For hypertension, you should declare all relationships with main is not mentioned in the manuscript. It is not mentioned in the work reported in this manuscript is the past 36 months.	ment to transparency and does not necessarily indicate rest, it is preferable that you do so. or example, if your manuscript pertains to the nufacturers of antihypertensive medication, even if
	Name all entities with whom you have this relationship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial plan	ining of the work
All support the presen manuscript funding, provision of study mate medical write article processing charges, et No time lin this item.	for None (e.g., ials, ing,	Circle to 4dy to 200 account toks
	Time frame: past 36 mg	onths
Grants or contracts fr any entity (indicated in item #1 abo	om S None	
Royalties o licenses	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	



12/13/2021

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	IX None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	K None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	1/22/2024
Your Name:	FARENDRA BHARDWAJ
Manuscript Title:	Effect of norethisterone dose and duration in the management of abnormal uterine
Manuscript Number (if known):	NILL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial plannin	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
-		Time frame: past 36 mon	ths · · · · ·
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

Or. FARENDRO BHARDWAJ
M885, MS, DNS (Obst. & Gynas) FMAS
M885, MS, DNS (Obst. & Gynas) FMAS
M885torit Professor, Dept. of Obst Confederate Form
Manetma Cunchi Medical Onlings & Hospital
Manetma Cunchi Medical Onlings & Hospital
Stagura, Jalpur-502022
RMC Rog. No. 32222

6		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments wer made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
5	Payment for expert testimony	None	
,	Support for attending meetings and/or travel	⊠ None	
	Patents planned, issued or pending	K None	
	Participation on a Data Safety Monitoring Board or Advisory Board	☐ None	
0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XL None	

Dr. FARENDRA BLAND DAVIAJ

ONLE DISCOSURE (Synae

Shapura, Jaipur-302022

RIAC Reg. No. 32222

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None	
13	Other financial or non-financial interests	I⊠ None	

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Dr. FARENDRA BHARDWAJ
MBBS, NS, DNB (Obst. & Gynee) IMAS
Assistant Professor, Dept. of Obst & Gynee
Mehetma Gendhi Nedicul College & Hospital
Sitapura, Jaipur-302022
RMC Reg. No. 32222

1/23/2024

SUBASH MALLYA

Date:

Your Name:

Manuscript Title: Manuscript Number (if known):		Effect of norethisterone dose and duration in the management of abnormal uterine	
		NILL	
aff inc	ntent of your manuscript. "R lected by the content of the r dicate a bias. If you are in do	we ask you to disclose all relationships/activities elated" means any relation with for-profit or no nanuscript. Disclosure represents a commitmen abt about whether to list a relationship/activity/ ities/interests should be defined broadly. For ex-	t-for-profit third parties whose interests may be it to transparency and does not necessarily interest, it is preferable that you do so.
ep tha	idemiology of hypertension, at medication is not mention	you should declare all relationships with manufa and in the manuscript. Port for the work reported in this manuscript wi	cturers of antihypertensive medication, even if
	1.77.37.34	e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	THE REAL PROPERTY.	Time frame: Since the initial planning	g of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		CE-CI, one talk-hay six relic and retrieves.
	medical writing, article processing charges, etc.) No time limit for this item.		
	1. 医物系	Time frame: past 36 mont	hs
2	contracts from any entity (if	None	
	not indicated in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees 🗵	None	
112/	13/2021/CMJE Disclosure Form		
	-1		
		Dr. SUBASH MALLY	YA.K
	9	PODMLS (Poor Cramitate Distorua in Ma Podmus (Poor Cramitate Distorua in Ma Consultani Gynacologist & Lapanos	woscney (Germany) ezot-sul System)
		iting No: 57735	

5	Payment or	₩ None
•	honoraria for	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	
6	Payment for expert testimony	☑ None
7	Support for attending	⊠ None
	meetings and/or travel	
8	Patents planned, issued or pending	□ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy	None
	group, paid or unpaid	
11	Stock or stock options	IS None
12	Receipt of	⊠ None
	13/2021/CMJE Disclosure	11 15 (V - N - N - N - N - N - N - N - N - N -

Dr. SUBASH MALLYA.K

DGO. DATA MALLYA.K

DGO. DATA MALLYA.K

DGO. DATA MALLYA.K

DGO. DATA MALLYA.K

Oraduate Diploma in Medical Legal System)

Impediogist & Laparoscopic Surgicon

Reg No: 57735

	equipment, materials, drugs, medical writing, gifts or other services	
13	Other financial or non-financial interests	ISI None
9		

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

PGD, DNB, MN.-165, District in Gyper Embessory (Germany)
PGDNLS Port Gradient District & Libertain Description
Committed Gyper Single & Libertain per Surgices
(Sag No. STES)

312/13/2021ICMJE Disclosure Form

Date:	3/4/2024
Your Name:	Dr. Rajat Singal
Manuscript Title:	Effect of norethisterone dose and duration in the management of abnormal uterine bleeding: A review
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	France Lectory as well resolved from
		Time frame: past 36 month	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	
		t to the following statement to indicate your agreement to answered every question and have not altered the wo	

Rojak Singal

Date:	3/4/2024
Your Name:	Dr. Sugandha Sharma
Manuscript Title:	Effect of norethisterone dose and duration in the management of abnormal uterine bleeding: A review
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Child the Nobley for wild additional week
		Time frame: past 36 mont	hs
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	⊗ None	
В	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	

I certify that I have answered every question and have not altered the wording of any of the questions on this form.



Date:	3/4/2024
Your Name:	Dr. Ashutosh Gautam
Manuscript Title:	Effect of norethisterone dose and duration in the management of abnormal uterine bleeding: A review
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	Class to Congress and administrations
	THE PERSON	Time frame: past 36 month	is.
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊗ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	
Plea		et to the following statement to indicate your agreement to answered every question and have not altered the wo	O